Search

Navya Basavaraju, Annamarie Jones, and Probal K Moulik detail the latest breakthrough in diabetes management [ABSTRACT FROM AUTHOR]

Copyright of Plastverarbeiter is the property of Hüthig GmbH and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The article informs The FDA has approved the MiniMed 780G System, the first insulin pump with meal detection technology. This advanced hybrid closed loop (AHCL) system automatically adjusts insulin delivery based on continuous glucose monitoring, improving glycemic control in patients with type 1 diabetes. While it offers benefits such as personalized insulin adjustments and improved time spent in euglycemic range.

The article presents the implementation of a real-time Hardware-in-the-Loop (HiL) system for control testing of an artificial pancreas. A model was used on a MyRIO device to simulate the glucose-insulin system, taking into account the effects of the glucose sensor and insulin pump. It was found that the system worked as expected and the results from the real test were consistent with the simulations performed. The model and the obtained results can be useful for the development of an artificial pancreas. [Extracted from the article]

Researchers have submitted a patent application for a "Support Device For Medication Delivery Device" to assist diabetic patients in managing their condition through insulin therapy. The device is designed to provide consistent depth of injection for insulin delivery, particularly for self-injection by patients. It includes features such as movable arms to pinch tissue, a guide for positioning the delivery device, and a holder for sliding the injection device to deliver medication. The patent application aims to address the need for improved devices to assist patients in managing diabetes effectively. [Extracted from the article]

Researchers have submitted a patent application for personalized event detection methods related to glucose monitoring in patients, particularly those with diabetes. The application focuses on using glucose measurements to determine the likelihood of a patient having consumed a meal during a specific interval, without relying on manual input. The goal is to improve patient outcomes by automating meal detection and glucose response analysis. The patent application was filed on June 20, 2024, and made available online on October 10, 2024. [Extracted from the article]

The patent "Connection and alignment detection systems and methods" by Medtronic MiniMed Inc. focuses on medical device systems for treating chronic diseases like diabetes by delivering medication to patients. The patent describes external pump-type delivery devices that can be connected to patients through tubing and needles, with mechanisms to assist in needle insertion. These devices allow for accurate doses of insulin to be delivered automatically, especially when used with glucose sensors. As pump technologies improve, the popularity of external medical infusion pump treatment is expected to increase over the next decade. [Extracted from the article]

A patent application has been submitted for a management process for insulin therapy using reinforcement learning and therapy escalation pathways. The application aims to develop a system that can monitor glucose control, provide frequent therapy intervention, and adjust therapy more frequently to improve outcomes for individuals with diabetes. The system involves performing a survey, high-touch interaction phase, and ongoing phase to adjust insulin therapy based on collected data and guidelines. This innovative approach seeks to enhance user adherence, outcomes, and satisfaction in managing diabetes. [Extracted from the article]

Researchers from the National and Kapodistrian University of Athens conducted a study on the impact of nutritional education at diabetes camps on glycemic control in children and adolescents with Type 1 Diabetes Mellitus (T1DM). The study found that the nutritional education offered at these camps had a beneficial effect on glycemic control during and after the camp sessions, although the effect was temporarily sustained. The researchers concluded that continuous nutritional education is necessary to prolong these positive outcomes and further studies are needed to evaluate the direct impact of nutritional education on glycemic control in this population. [Extracted from the article]

Researchers have submitted a patent application for a cannula assembly designed for a wearable drug delivery device, focusing on improving manufacturing processes and ensuring a reliable sealing connection between a soft cannula and a rigid cannula. The device aims to provide subcutaneous drug delivery, particularly for insulin treatment, over an extended period. The patent application outlines the design and manufacturing steps for the cannula assembly, emphasizing the importance of a fluid-tight connection for reliable drug delivery. [Extracted from the article]

A patent application titled "Dual Piezoelectric Stack Plunger Sub-Assembly" by inventor Alessandro E. PIZZOCHERO has been published online by the USPTO, with Becton Dickinson and Company as the assignee. The invention relates to a plunger sub-assembly for delivering liquid pharmaceutical products, specifically insulin therapy for diabetic patients. The application describes a piezoelectric actuator design for fluid medication delivery methods and pumps, aiming to address the disadvantages of existing insulin pumps by reducing size and complexity while improving functionality. [Extracted from the article]

A patent has been issued to Tandem Diabetes Care Inc. for enhanced confirmations for touchscreen infusion pumps, developed by inventor Michael J. Rosinko. The patent aims to reduce user errors in programming pump parameters by requiring users to trace a pictorial icon related to the parameter on the touchscreen for confirmation. This innovation enhances user awareness and reduces the likelihood of mistakenly confirming incorrect programming instructions, ultimately improving patient safety and the effectiveness of medicament therapy. [Extracted from the article]

A patent has been issued to Insulet Corporation for occlusion resolution in medication delivery devices, systems, and methods. The patent focuses on methods, devices, and systems that aim to differentiate between occlusions that require user intervention and those that do not, particularly in the context of delivering insulin to individuals with diabetes. By incorporating feedback from occlusion sensors and physiological feedback from patients, these innovations seek to improve the accuracy and safety of automated medication delivery. The patent outlines various techniques for detecting and addressing occlusions in an automated medication delivery system, emphasizing the importance of timely and effective medication administration while minimizing user stress and potential health risks. [Extracted from the article]

A patent application titled "Plate With Integral Fluid Path Channels" by Biehler, Gyory, and Pizzochero, assigned to Becton Dickinson and Company, focuses on improving insulin delivery for diabetic patients. The application discusses the challenges of diabetes management, different treatment options, and the advantages of infusion pump therapy. The invention aims to provide a patch pump device with fluid channels that efficiently deliver medication while reducing the overall size and complexity of the device. This innovation could potentially enhance the quality of life for diabetic patients by improving insulin therapy. [Extracted from the article]

A pilot study, NCT06633952, aims to improve cognition and wellbeing in adults with mild cognitive impairment (MCI) through a combination treatment of non-invasive brain stimulation and digital cognitive interventions. The study involves the use of a tablet-based cognitive training game, meditation-inspired cognitive interventions, and noninvasive neurostimulation devices. The research focuses on assessing changes in cognitive performance, sleep metrics, stress levels, and everyday cognition in participants aged 60-85 years. The study is recruiting participants and is set to be completed by December 31, 2025. [Extracted from the article]

A pilot study is being conducted to investigate the impact of personalized digital meditation on improving sleep and reducing stress in patients with mild cognitive impairment (MCI). The study aims to test the hypothesis that treatment with a novel form of closed-loop digital meditation will lead to cognitive improvements in MCI patients compared to those without cognitive impairment. The study involves the use of a tablet-based meditation-inspired cognitive training game called MediTrain, along with wrist-worn multi-sensor watches and sleep monitors to collect data on stress and sleep metrics. [Extracted from the article]

A patent application by Becton Dickinson and Company for a self-contained spring inserter for a drug delivery infusion device has been made available online. The invention aims to provide an infusion set that incorporates an integral introducer needle to facilitate cannula insertion, reducing the number of components a user must carry and preventing accidental needle sticks. The infusion set also has the potential to include an integrated sensor, such as a blood glucose sensor, to monitor blood levels. The patent application provides detailed information on the method and device for inserting the catheter and introducer needle, as well as the design and functionality of the infusion set. [Extracted from the article]

The patent application titled "Blood Glucose States Based On Sensed Brain Activity" proposes a non-invasive method for predicting a person's glucose state using wearable sensors that sense brain activity signals. The system, which can be personalized and trained on personal data, includes a device with processors and memory that store computer-program instructions. These instructions allow the device to predict the person's glucose state based on the sensed brain activity signals and provide instructions for communication about the predicted glucose state. The patent application provides detailed information about the method and features of the system, offering an alternative to traditional glucose sensors that may benefit both diabetic and non-diabetic individuals. [Extracted from the article]

Medtronic MiniMed Inc. has been issued a patent for configurable target values related to infusion pump therapy for delivering medication, such as insulin, to patients. The patent describes techniques for identifying target glucose values based on user input, determining fluid delivery commands to regulate glucose levels, and causing fluid delivery by a fluid infusion device. The invention aims to improve glucose control and reduce manual errors in managing therapy for diabetics. This patent provides valuable information for researchers interested in medical devices and healthcare technology. [Extracted from the article]

A patent has been issued to Becton Dickinson and Company for an infusion device with a stabilizer member. The device is designed to address concerns related to disconnecting tubing without pulling out the catheter, as well as difficulties in removing needle guards. The device includes a base, a fluid connector, and a needle hub assembly with a moveable needle shield. The needle shield has stabilizing members, such as legs, that engage the needle hub to prevent separation or sliding movement. The invention aims to provide improved infusion devices that enhance patient safety and ease of use. [Extracted from the article]

A patent application by inventor Cuijun Yang has been made available online for an interlocking drug infusion device and artificial pancreas. The device aims to prevent over-infusion of insulin in diabetic patients by using a program module and position detection module to provide driving instructions to the actuator. This interlock mechanism ensures that the device continues to function even in the event of electronic component failure, reducing the risk of hypoglycemia or coma. The invention also includes an elastic member to reset the driving unit and various arrangements for the position detection element. The patent application was filed by Medtrum Technologies Inc. and is part of ongoing efforts to improve diabetes management technology. [Extracted from the article]

A recent study conducted at the University of Western Australia explored the experiences of youth with type 1 diabetes who were at high risk of complications and began using advanced hybrid closed-loop (AHCL) therapy in a clinical trial setting. The study found that AHCL therapy improved glycemia, but participants reported ongoing motivation issues and suboptimal use of the system. They also expressed the need for increased psychosocial and clinical support. The research concluded that ongoing monitoring and interventions to enhance psychological care are crucial for youth with suboptimal diabetes management. [Extracted from the article]

A patent application has been filed for a medical system that manages critical events in patients. The system includes medical devices that deliver therapy to patients and a processing system that determines critical events and their severity. The system then communicates these critical events to healthcare providers using various communication techniques. The system aims to improve patient care by identifying and managing critical events effectively. The patent application provides detailed claims and additional information for further reference. [Extracted from the article]

Medtronic has been notifying users of its MiniMed insulin pumps to be aware of potentially short battery lives, and to heed low-power warnings. [ABSTRACT FROM AUTHOR]

This document provides information about a clinical study, NCT06598865, that is being conducted in France. The study aims to evaluate the effectiveness of Adapted Physical Activity (APA) on glycemic regulation in individuals with unbalanced Type 2 Diabetes. The study will involve 120 participants who will receive regular support from an APA instructor and will be asked to participate in three sessions per week of APA. The study is not yet recruiting participants and is expected to be completed by June 2028. [Extracted from the article]

A new large-scale study led by the Keck School of Medicine of USC aims to investigate how type 1 diabetes affects brain development in children. The study will involve 12 research centers across the United States and will examine the environmental, lifestyle, social, and clinical factors that impact brain development in children newly diagnosed with diabetes. The study, supported by a grant from the National Institutes of Health, will recruit a diverse group of participants and could lead to improved clinical guidelines and targeted treatments for type 1 diabetes. Advanced tools such as continuous glucose monitors and functional magnetic resonance imaging will be used to gather data on glucose levels and brain structure and function. [Extracted from the article]

A patent application titled "Determining A Wireless Communication Interface For Communicating In A Network Including A Medical Device" has been published online. The application discusses the use of wireless communication interfaces in medical devices, specifically insulin infusion systems. The invention aims to determine the most suitable wireless communication interface based on factors such as proximity, quality of service, and security level of data. The application provides details on various wireless communication interfaces and their potential applications in medical devices. [Extracted from the article]

Tandem Diabetes Care, Inc. has announced that its t:slim X2 insulin pump with Control-IQ automated insulin delivery technology is now approved for use with Eli Lilly and Company's Lyumjev ultra-rapid acting insulin in the European Union. This compatibility offers more flexibility for customers in the EU and was supported by a clinical trial showing the benefits of using Lyumjev with Control-IQ technology. Tandem and Lilly are working to secure Lyumjev compatibility for the t:slim X2 pump in other regions and for the Tandem Mobi pump. The t:slim X2 pump is already cleared for use with other insulins globally. [Extracted from the article]

Researchers from Dartmouth College have conducted a study on diabetes mellitus management, specifically focusing on mealtime prediction using wearable insulin pump data. The research aims to develop personalized models for predicting future mealtimes to support timely insulin dose administration. The study found that the majority of patients with diabetes have irregular and inconsistent mealtime patterns, and they demonstrated the feasibility of predicting future mealtimes with high accuracy. The researchers hope that their findings will lay the groundwork for developing a meal prediction system that can help patients with diabetes reduce post-meal high blood glucose levels. [Extracted from the article]

A patent application titled "Predictive Infusion Device Operations And Related Methods And Systems" has been published online. The application discusses techniques for fluid delivery in medical devices, specifically infusion pumps used to deliver medication to patients. The techniques involve monitoring a user's physiological condition and transitioning between different operational modes of the device based on the condition. The application also mentions the use of predictive algorithms to estimate future blood glucose levels for regulating insulin delivery. The inventors provide a system and method for implementing these techniques. [Extracted from the article]

A patent application by inventor Mark C. Estes describes an infusion pump system that incorporates near field communication (NFC) technology to enhance user communication with the pump. NFC allows for the convenient sharing of user commands or data to the pump system, simplifying the input process. The system can receive data from NFC tags, which can be used to rapidly indicate the amount of food or carbohydrates to be consumed for a meal. The system can also write data to NFC tags, such as backup copies of user settings. The patent application also mentions the use of accelerometers to activate NFC communication when a certain level of movement is detected. The system may include a portable pump housing, a pump drive system, control circuitry, and an NFC circuit. The patent application also discusses the possibility of a separate remote-control device with NFC functionality. The system can be used for insulin delivery and includes a prompt for the user to confirm or deny suggested bolus dosages of insulin. The patent application provides detailed descriptions of various embodiments and methods for controlling the infusion pump system. [Extracted from the article]

A patent has been issued to Medtronic MiniMed Inc. for a contextual adjustment system for insulin absorption curves. The system uses demographic data and current contextual information to identify a reference insulin absorption curve for a patient and then adjusts it based on the contextual adjustment factor. This allows for more accurate insulin delivery to patients, taking into account variations in insulin response caused by factors such as time of day, activity level, and geographic location. The system utilizes machine learning and historical data to optimize insulin absorption models. [Extracted from the article]

A patent application has been submitted for a method of predicting a person's blood glucose state based on sensed brain activity. The method involves using wearable sensing devices with electrodes placed on the head to sense brain activity signals. These signals are then inputted into a model or algorithm that has been trained to predict the person's glucose state. The predicted glucose state can be communicated to the person or their care team through various means, such as a display on a personal device or alerts. This method could be beneficial for diabetic patients, as well as individuals who want to monitor their glucose levels for overall health and well-being. The patent application was filed in March 2024. [Extracted from the article]

A patent application titled "Blood Glucose States Based On Sensed Brain Activity" is currently being reviewed. The inventors propose a method of predicting a person's glucose levels by analyzing brain activity signals. This can be done using wearable devices placed on the head, which transmit the signals to a trained model or algorithm for prediction. The system can provide real-time glucose values, connect with a care team, and offer recommendations for meals and exercise. The patent application also describes a wearable sensor that can be worn behind the ear, with options for additional features like an inertial sensor or a photoplethysmography sensor. [Extracted from the article]

A patent application titled "Blood Glucose States Based on Sensed Brain Activity" has been published online. The inventors propose a method for predicting a person's glucose state by sensing brain activity signals using wearable sensing devices placed on the head. The sensed signals are inputted into a trained model or algorithm to predict the glucose state, which can be displayed on a personal device or communicated to a care team. The method also allows for input of additional data and can provide automated recommendations for meals and exercise. The patent application provides detailed claims and additional information for further exploration. [Extracted from the article]

A patent application by the inventors from the Board of Trustees of the Leland Stanford Junior University describes systems and methods for predictive glucose management. The invention involves a glucose management device that includes a brain signal recorder and a controller. The device records a user's brain activity signal and decodes it to predict future glucose levels. The device can provide warnings, deliver therapy, and validate predicted glucose levels. The invention aims to manage glucose levels in a desired therapeutic range. [Extracted from the article]

A recent report from the Massachusetts Institute of Technology (MIT) evaluates the performance of glucose-responsive glucagon (GRG) therapeutics in reducing the risk of severe hypoglycemia in diabetes mellitus. The study uses computational models to analyze the kinetics of activation and compares two distinct GRG designs. The results show that both designs require refinement to accurately describe clinical data involving insulin, glucose, and glucagon dynamics. The study also introduces a new element to the model for simulating insulin and glucagon infusion pumps. This research highlights the need for improved glucagon models and provides valuable insights for the development of GRG technologies. [Extracted from the article]

Altitude changes during air travel may affect the blood glucose levels of individuals with type 1 diabetes who use insulin pump therapy, according to a study presented at the Annual Meeting of The European Association for the Study of Diabetes. The study tested insulin delivery from 26 insulin pumps in a hypobaric chamber that simulated the atmospheric changes during a commercial flight. The researchers found that insulin cartridges over-delivered during ascent and under-delivered during descent, which could slightly affect blood glucose levels. In the event of a sudden decompression of the cabin, there is a risk of insulin overdose, but individuals can counter this by ingesting extra short-acting carbohydrates. The study suggests that individuals using insulin pumps should be aware of the potential impact of changes in cabin air pressure on insulin delivery and consider temporarily disconnecting their pumps before take-off. [Extracted from the article]

A new report discusses research findings on hyperglycemia and its relationship to insulin pump therapy. The study found that interruption of insulin flow can lead to a rise in blood glucose levels and blood beta-hydroxybutyrate ketone levels. The research identified eight relevant studies that measured these levels following suspension of continuous subcutaneous insulin infusion. The findings suggest that moderate to severe hyperglycemia can occur within 5-9 hours, and moderate to severe ketonemia can occur within 7-12 hours after insulin pump occlusion. Patients and clinicians should be aware of these timing factors when considering the risks of developing metabolic complications. [Extracted from the article]

Insulet Corporation has been issued a patent for alarms and alerts for medication delivery devices and systems. The patent describes a networked medication-delivery system that includes an analyte sensor, a medication delivery device, and a remote user-interface device. The system aims to improve the management of diabetes by providing better communication and feedback between the user and the medication delivery device. Additionally, Insulet Corporation has filed a patent application for a wireless communication system that can be used in medical devices such as infusion pumps. This system aims to improve the management of glucose metabolism disorders, specifically hypoglycemia, by using wireless technology to monitor and control the delivery of proinsulin. The patent application highlights the potential benefits of this wireless communication system in the field of health and medicine. [Extracted from the article]

The US Patent and Trademark Office has published a patent application for a remote alarm system for wearable medical devices. The system is designed to improve the perception of alarms and messages for patients and bystanders. It can also communicate with emergency personnel and send messages to caregivers or relatives. The application provides detailed descriptions and claims for the invention, which combines a light bulb with a cardio device to provide more accessible and efficient treatment during cardiac emergencies. This information may be useful for researchers and individuals in the field of health and medicine. [Extracted from the article]

A patent application has been submitted for a new medical device that aims to improve the accuracy of continuous analyte sensors used in therapy delivery systems. The device would regulate the delivery of fluid medication based on the accuracy of the sensor-generated values, allowing for more precise and personalized treatment. The patent application was filed by inventors from various locations in the United States and is currently awaiting approval. This development could have significant implications for the management of conditions such as diabetes. [Extracted from the article]

A case report in the journal Reactions Weekly describes a 29-year-old woman with type 1 diabetes who experienced hypoglycemia after intentionally overdosing on insulin. The woman was admitted to the hospital for investigation of cyclical vomiting syndrome and her diabetes was managed using an insulin pump. Analysis of the pump data revealed that she had been manipulating the fill cannula function to administer excessive amounts of insulin, leading to hypoglycemia. This case highlights the potential dangers of intentional insulin overdose and the importance of monitoring and support for individuals with diabetes. [Extracted from the article]

The article provides information on a patent issued for infusion device and methods, assigned to Sanofi. The inventors including Joseph Butler, Paul Richard Draper, and Frank Erbstein filed the patent on January 12, 2022 and published it online on August 27, 2024. Also mentioned are background information supplied by the inventors, inventors' summary information supplied for the patent, and the claims supplied by the inventors.

This patent application discusses the development of medical devices for monitoring and maintaining analyte levels, specifically focusing on glucose monitoring devices and insulin infusion pumps for people with diabetes. The devices have features that alert users when their analyte levels fall within certain ranges of concern, and alarm features that warn users when their levels reach high concern ranges. The devices also have reminder features that prompt users to take another measurement after a certain period of time. The alerts, alarms, and reminders can be conveyed visually, audibly, or through vibrations. The patent application describes a computing device that communicates with a skin-mounted assembly containing a glucose sensor and transmitter, allowing for individual access level rights and the transmission of data to a data management system. Notifications can be sent to the device based on these permissions, including glucose level data, trend information, and alert conditions. The invention also includes the use of visual, audible, or vibratory reminders for alerts, alarms, and reminders. [Extracted from the article]

This text describes a patent for an electrical connection used in active implantable medical devices (AIMDs). The patent discusses a filter feedthrough and a feedthrough assembly that both utilize an anisotropic conductive layer. The anisotropic conductive layer is responsible for connecting different components of the AIMD. The patent provides different variations and embodiments of the invention. The assignee for this patent is Greatbatch Ltd. [Extracted from the article]

A patent has been issued to Insulet Corporation for an infusion pump system and method. The system incorporates near field communication (NFC) technology to enhance user communication with the pump. Users can transfer data to the pump system using pre-programmed NFC tags, simplifying the input of information such as food intake or physical exercise. The system also includes an accelerometer to activate NFC communication when a certain level of movement is detected. The patent outlines various configurations and options for the infusion pump system, including the use of a separate NFC communicator device and a remote-control device. [Extracted from the article]

A patent application for a user-wearable infusion pump holder has been filed by inventors Philip Sven Lamb and John Charles Nadworny. The holder is designed to securely hold and carry a user-wearable infusion pump, allowing for easy removal and insertion of the pump. The system includes a retention frame and an elastic sleeve that stretches to enable insertion of the pump onto the frame and flexes back to provide a force biasing the pump on the frame. The invention aims to provide a more versatile and secure way to hold and carry a user-wearable infusion pump. [Extracted from the article]